SML2303
Tosedostat
≥98% (HPLC)
别名:
2S-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methylpentanoyl-amino]-2-phenylethanoic acid cyclopentyl ester, CHR-2797
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H30N2O6
化学文摘社编号:
分子量:
406.47
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI
1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1
SMILES string
CC(C)C[C@H]([C@H](O)C(NO)=O)C(N[C@@H](C1=CC=CC=C1)C(OC2CCCC2)=O)=O
InChI key
FWFGIHPGRQZWIW-SQNIBIBYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Biochem/physiol Actions
Potent cell permeable, antiproliferative aminopeptidase inhibitor
Tosedostat (CHR-2797) is a potent cell permeable, antiproliferative aminopeptidase inhibitor. It has been in clinical trials for AML, pancreatic cancer and more.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Raya Mawad et al.
British journal of haematology, 172(2), 238-245 (2015-11-17)
Tosedostat, an oral aminopeptidase inhibitor, has synergy with cytarabine and hypomethylating agents. We performed a Phase II trial to determine rates of complete remission (CR) and survival using tosedostat with cytarabine or decitabine in older patients with untreated acute myeloid
Caner Saygin et al.
Journal of hematology & oncology, 10(1), 93-93 (2017-04-20)
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either
Danielle Shafer et al.
Blood reviews, 30(4), 275-283 (2016-03-15)
Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite improvements in our understanding of the disease, treatment has changed minimally and outcomes remain poor for the majority of patients. Within the last decade, there have been
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持